FDA
FDA Warns Indian Toothpaste Maker Over Long-Delisted Color Additive
The FDA has issued a warning letter to Pritam International Private Limited over a prohibited color additive and manufacturing violations at its Indian facility. Published Nov. 3, 2026, the letter follows a U.S. recall covering more than 4 million tube...
FDA clears exaluren IND for U.S. participation in Eloxx's Phase 2 ADPKD trial
Eloxx Pharmaceuticals can begin opening U.S. sites for its global EXPRESS trial after the Food and Drug Administration cleared an Investigational New Drug application for exaluren, the company announced on October 29, 2026. The Phase 2 study will evalu...
Mississippi AG Fitch Calls on National Security Council to Safeguard GLP-1 Drug Supply Chain from Chinese Exploitation
Attorney General Lynn Fitch joins 19 other state attorneys general in urging the administration to protect against Chinese efforts to introduce unsafe pharmaceutical ingredients into the U.S. market, citing recent violations of FDA safeguards for popul...
South Korea to Introduce Medication Abortion Pills as Early as First Quarter 2025
Government announces plan to approve mifepristone for pregnancies up to nine weeks, with doctors to dispense directly for two years. Medical and religious groups raise concerns over incomplete legal framework....
General Mills completa la eliminación de colorantes artificiales de todos sus cereales en EE.UU.
La compañía de alimentos cumplió con anticipación su compromiso de eliminar tintes sintéticos de productos como Lucky Charms y Trix, utilizando ahora colorantes naturales derivados de frutas, verduras y especias....
Rosen Law Firm Announces Class Action Lawsuit Against Aardvark Therapeutics Over Drug Safety Disclosures
Law firm Rosen announces securities class action against Aardvark Therapeutics following FDA clinical hold on lead drug candidate ARD-101, with investors facing an October 13, 2026 deadline to seek lead plaintiff status....
FDA Clears Orum Therapeutics to Begin Testing Novel Leukemia Drug ORM-1153
The FDA has authorized Orum Therapeutics to proceed with human trials of ORM-1153, a first-in-class degrader-antibody conjugate targeting acute myeloid leukemia and other blood cancers. The Phase 1 study is expected to launch by year-end 2026....